​

Savara Stock (NASDAQ:SVRA)

ForecastOwnershipFinancialsChart
Savara by TradingView

Previous Close

$3.23

52W Range

$2.81 - $5.70

50D Avg

$3.48

200D Avg

$4.21

Market Cap

$554.33M

Avg Vol (3M)

$1.43M

Beta

1.02

Div Yield

-

SVRA Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

37

IPO Date

Apr 28, 2017

Website

SVRA Performance

SVRA Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-60.01M$-38.84M$-41.48M
Net Income$-54.70M$-38.95M$-45.30M
EBITDA$-59.83M$-37.88M$-40.27M
Basic EPS$-0.33$-0.25$-0.34
Diluted EPS$-0.33$-0.25$-0.34

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q2 20Aug 06, 20 | 9:03 PM
Q1 20May 07, 20 | 6:52 PM
Q4 19Mar 12, 20 | 10:59 PM

Peer Comparison

TickerCompany
SRRKScholar Rock Holding Corporation
RVMDRevolution Medicines, Inc.
ANABAnaptysBio, Inc.
STOKStoke Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
FENCFennec Pharmaceuticals Inc.
ALXOALX Oncology Holdings Inc.
TRDAEntrada Therapeutics, Inc.
DYNDyne Therapeutics, Inc.
XOMAXOMA Corporation
IKNAIkena Oncology, Inc.
EWTXEdgewise Therapeutics, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
GPCRStructure Therapeutics Inc.
RZLTRezolute, Inc.
TPSTTempest Therapeutics, Inc.
XLOXilio Therapeutics, Inc.
PTIXProtagenic Therapeutics, Inc.
KZRKezar Life Sciences, Inc.
ACLXArcellx, Inc.
TARAProtara Therapeutics, Inc.